Key Points
- Director Robert Malenka sold 12,116 shares on Feb. 13 at an average price of $18.21 for $220,632, reducing his ownership by 3.45% to 339,254 shares (worth about $6.18M).
- Maplight reported a staggering quarterly loss of ($37.18) EPS versus a consensus of ($1.86), missing estimates by $35.32.
- Despite the miss, analysts hold a "Moderate Buy" consensus with an average target of $31 and mixed ratings, while Jefferies and Morgan Stanley initiated coverage with $32 and $34 targets respectively.
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) Director Robert Malenka sold 12,116 shares of the company's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $18.21, for a total value of $220,632.36. Following the completion of the sale, the director owned 339,254 shares in the company, valued at approximately $6,177,815.34. This represents a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Maplight Therapeutics Stock Up 0.3%
NASDAQ:MPLT opened at $17.31 on Thursday. The company has a market capitalization of $785.35 million and a PE ratio of -0.47. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $21.55. The firm has a 50 day moving average price of $18.03.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on MPLT shares. Wall Street Zen raised Maplight Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, December 20th. Jefferies Financial Group assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a "buy" rating and a $32.00 price target on the stock. Weiss Ratings began coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a "sell (e)" rating on the stock. Morgan Stanley assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an "overweight" rating and a $34.00 target price for the company. Finally, Zacks Research raised Maplight Therapeutics to a "hold" rating in a research note on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.00.
Get Our Latest Analysis on MPLT
Hedge Funds Weigh In On Maplight Therapeutics
Several institutional investors have recently modified their holdings of the business. Strs Ohio bought a new position in Maplight Therapeutics in the 4th quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Maplight Therapeutics in the 4th quarter worth about $70,000. New York State Common Retirement Fund bought a new position in Maplight Therapeutics during the fourth quarter valued at about $93,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at about $172,000. Finally, Walleye Capital LLC purchased a new stake in Maplight Therapeutics during the fourth quarter worth about $205,000.
About Maplight Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
